CHDI Foundation's Annual Huntington’s Disease Therapeutics Conference in Palm Springs

The annual CHDI Foundation's Annual Huntington’s Disease Therapeutics Conference is just around the corner. The Harness team will be out in force, and look forward to connecting with drug developers, researchers and patient groups striving to deliver novel therapeutic approaches to the disease.

Our CSO, Andy Billinton will be presenting on Harness’ FAN1 upregulation approach to Huntington’s and other triplet repeat disorders.

hashtag#CHDI2026 hashtag#HarnessTherapeutics hashtag#MISBA hashtag#HuntingtonsDisease hashtag#NeurodegenerativeDiseases

Our programmes

Huntington's Disease

Discover more

ALS and Alzheimer's

Discover more

Our news

February 2026

Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntington’s Disease and Establishes Clinical Advisory Board

October 2025

Harness Therapeutics Announces Launch of MISBA® Duo Platform and Research Collaboration with Ono Venture Investment

June 2025

Harness Therapeutics Publishes HTT CAG Repeat Sizing Methodology Code on GitHub

February 2025

Harness Therapeutics to Present Nanopore Sequencing Data for Detecting CAG Expansion in the Huntingtin Gene at CHDI Huntington’s Disease Therapeutics Conference

View all